Evidence map›Paper›PMID 42471662›Full record

ReviewMolecular cancer2026

Protein lactylation in cancer: principles, programmes and therapeutic opportunities.

Xiaoyun Bu, Xinyue Yu, Jie Wang, Mingjing Peng, Min Su, Yanyan Tang, Jie Jiang, Xia Luo, Mingzhi Xia, Yong Yi and 1 more

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoyun Bu *Department of Colorectal Surgery, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, China.
Xinyue Yu *Center of Growth, Metabolism and Aging, Key Laboratory of Bio-Resource and Eco-Environment, Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, China.
Jie WangDepartment of Pathology, Institute of Oncology, The School of Basic Medical Sciences & Diagnostic Pathology Center, Fujian Medical University, Fuzhou, Fujian, China.
Mingjing PengHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Min SuHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Yanyan TangHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Jie JiangHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Xia LuoHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Mingzhi XiaHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China.
Yong YiCenter of Growth, Metabolism and Aging, Key Laboratory of Bio-Resource and Eco-Environment, Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, China. yy-yiyong@scu.edu.cn.
Xianjie JiangHunan Key Laboratory of Cancer Metabolism, the Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China. xjjiang2011@163.com.

Funding

High-Level Talent Support Program of Hunan Cancer Hospital 20250805-1003High-Level Talent Support Program of Hunan Cancer Hospital 20250807-1002Scientific Research Project of Hunan Provincial Health Commission 20256912the Joint Funds for the Innovation of Science and Technology, Fujian Province 2025Y9120the National Natural Science Foundation of China 82202966the Natural Science Foundation of Hunan Province 2024JJ6287the Natural Science Foundation of Hunan Province 2026JJ80901the science and technology innovation Program of Hunan Province 2023RC3199
6 · The paper itself

Abstract

Lactylation is a recently identified metabolism-associated post-translational modification that provides a mechanistic link between tumor metabolic reprogramming and epigenetic regulation. Although aberrant lactate accumulation in tumor tissues has long been recognized, a comprehensive and unified understanding of how lactate-derived modifications contribute to tumor initiation and progression remains lacking. Here, we use lactate metabolism as a conceptual framework to systematically review the biogenesis and regulatory networks of lactylation, with a particular focus on its functions and underlying molecular mechanisms in key malignant processes, including tumor proliferation, invasion and metastasis, angiogenesis, immune evasion, radiotherapy resistance and systemic therapy resistance. Furthermore, we review emerging anti-tumor therapeutic strategies targeting lactate metabolism and tumor lactylation, highlighting that glucose metabolism-driven lactate accumulation and lactylation play a pivotal role in sustaining tumor cell survival and immunosuppressive phenotypes. Inhibition of lactate metabolism markedly attenuates tumor-associated lactylation and exhibits substantial synergistic efficacy when combined with other anti-tumor therapies. Overall, this work advances a systematic understanding of the roles of lactylation in tumor malignant progression and provides an important conceptual and theoretical foundation for the development of novel cancer therapeutic strategies targeting protein lactylation.

Indexed as

Lactic AcidNeoplasmsProtein Processing, Post-TranslationalAnimalsHumansMetabolic ReprogrammingLactic AcidAngiogenesisImmune evasionLactylationMetastasisProliferationRadiotherapy resistance, systemic therapy resistanceTumor progression

Identifiers

PMID42471662
PMCPMC13670569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.